Haemodynamic effects of the calcium facilitator Bay K-8644 in rats following vascular calcium overload.

1. The haemodynamic effects of the Ca2+ facilitator Bay K-8644 (Bay) were studied in a model of calcinosis induced by acute treatment with vitamin D3 and nicotine administration over 4 days with 13 days of recovery. 2. Calcium content of the left ventricular myocardium increased 8-9 fold, while aortic Ca2+ levels increased up to 12-fold in treated animals. There were minimal changes in the ECG and no change in the level of plasma alpha-hydroxy-butyrate-dehydrogenase, a cardiac specific enzyme which increases during ischaemia. Significant increases in pulse pressure (PP) were seen in anaesthetized and conscious calcinotic rats, with no increase in cardiac output index (DABF) or systemic vascular resistance. However, aortic rigidity (AORI) was significantly elevated in the calcinotic group under anaesthesia. 3. In both control and calcinotic rats, pressor responses to i.v. Bay were exclusively mediated by an increase in aortic blood flow (DABF) as lower body vascular resistance (TLBVR) did not change. The increase in DABF at low doses (0.1-1 microgram kg-1) of Bay probably resulted from an increase in venous return induced by the agonist, as Bay had little effect on cardiac contractility over this dose range (as estimated by left ventricular dp/dtmax) and did not cause tachycardia. At higher doses (10-1000 micrograms kg-1), Bay significantly increased LV dp/dt. Bay caused dose-related increases in AORI in pithed calcinotic rats, but a decrease in AORI in control animals. 4. The calcinosis model, which incorporates a recovery period to obviate the acute effects of nicotine and/or vitamin D3 treatment, results in long-term tissue calcium accumulation.(ABSTRACT TRUNCATED AT 250 WORDS)

[1]  M. Böhm,et al.  Positive inotropic effect of bay K 8644: cAMP-independence and lack of inhibitory effect of adenosine , 1985, Naunyn-Schmiedeberg's Archives of Pharmacology.

[2]  J. Atkinson,et al.  Vascular Calcium Overload Produced by Administration of Vitamin D3 and Nicotine in Rats. Changes in Tissue Calcium Levels, Blood Pressure, and Pressor Responses to Electrical Stimulation or Norepinephrine in Vivo , 1990, Journal of cardiovascular pharmacology.

[3]  M. Safar Pulse pressure in essential hypertension: clinical and therapeutical implications. , 1989, Journal of hypertension.

[4]  C. Maggi,et al.  Multiple mechanisms in the motor responses of the guinea‐pig isolated urinary bladder to bradykinin , 1989, British journal of pharmacology.

[5]  A. Salvetti Angiotensin-converting enzyme inhibitors in the treatment of mild to moderate essential hypertension. , 1989, American journal of hypertension.

[6]  S. Laurent,et al.  Calcium‐Entry Blockers and Arterial Compliance in Hypertension , 1989, Journal of cardiovascular pharmacology.

[7]  M. Frey,et al.  The role of calcium in the pathogenesis of experimental arteriosclerosis , 1987 .

[8]  M. Frey,et al.  Antihypertensive and arterial anticalcinotic effects of calcium antagonists. , 1986, The American journal of cardiology.

[9]  C. E. Hock,et al.  Mechanism of the pressor effect of the calcium agonist, BAY k 8644, in the intact rat. , 1986, Pharmacology.

[10]  M. Frey,et al.  Experimental basis of the long-term therapy of arterial hypertension with calcium antagonists. , 1985, The American journal of cardiology.

[11]  E. Mikkelsen Comparison of effects of a new dihydropyridine, Bay K 8644, and nifedipine on spontaneous mechanical activity in rat portal vein , 1985, British journal of pharmacology.

[12]  M. Schramm,et al.  Novel dihydropyridines with positive inotropic action through activation of Ca2+ channels , 1983, Nature.

[13]  E. Chain,et al.  Abrupt reoxygenation of the anoxic potassium-arrested perfused rat heart: a study of myocardial enzyme release. , 1973, Journal of molecular and cellular cardiology.

[14]  J. Gillespie,et al.  A method of stimulating the complete sympathetic outflow from the spinal cord to blood vessels in the pithed rat. , 1967, British journal of pharmacology and chemotherapy.